Radiopharmaceuticals and Tracers

This channel includes news and new technology innovations for nuclear and molecular imaging agents, radiotracers and radiopharmaceuticals used in PET or SPECT imaging. This includes advances in myocardiac perfusion agents.

IBA Molecular, acquisition, Mallinckrodt Nuclear Imaging, nuclear imaging
News | Nuclear Imaging | January 30, 2017

January 30, 2017 — IBA Molecular has successfully completed its acquisition of Mallinckrodt Nuclear Imaging,...

News | Radiopharmaceuticals and Tracers | January 17, 2017

January 17, 2017 — NorthStar Medical Technologies LLC has received additional matching funds from the U.S....

Medrad Intego PET Infusion System, recall
News | Nuclear Imaging | January 12, 2017

January 12, 2017 — Bayer Healthcare has initiated a recall of all its Medrad Intego PET Infusion System Source...

News | Radiopharmaceuticals and Tracers | January 06, 2017

January 6, 2017 — New research demonstrates that a novel...

metastatic colorectal cancer, mCRC, Sirtex, NCCN guidelines, Y-90 microspheres
News | Radiation Therapy | January 03, 2017

January 3, 2017 — Sirtex Medical Limited announced in December that SIR-Spheres Y-90 resin microspheres have been...

SNMMI Develops USP Recommendations for Compounded Sterile Radiopharmaceuticals
News | December 28, 2016

December 28, 2016 — The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has developed United States...

prostate, CT scan, Dave Fornell medical
News | Prostate Cancer | December 22, 2016

Cancer Targeted Technology (CTT), a privately-held Seattle-based biotechnology firm focusing on cancer diagnostics...

News | Prostate Cancer | December 14, 2016

December 14, 2016 — Cancer Targeted Technology (CTT), a privately-held Seattle-based biotechnology firm focusing on...

News | Nuclear Imaging | December 12, 2016

Molecular Targeting Technologies, Inc. (MTTI) announces that response of colorectal cancer to treatment can be...

Alzheimer's disease, early diagnosis, PET scans, imaging compound, Fluselenamyl

Researchers at Washington University School of Medicine in St. Louis have developed a chemical compound that detects the Alzheimer’s protein amyloid beta better than current FDA-approved agents. The compound potentially may be used in brain scans to identify people in the earliest stages of Alzheimer’s disease. In the image, the compound has passed from the bloodstream of a living mouse into its brain, where it is detected by a positron emission tomography (PET) scan. Arrows indicate clumps of amyloid beta. Credit Ping Yan and Jin-Moo Lee.

News | Radiopharmaceuticals and Tracers | November 02, 2016

November 2, 2016 — By the time unambiguous signs of memory loss and cognitive decline appear in people with...

NAS report, National Academies of Sciences Engineering and Medicine, Mo-99 production, highly enriched uranium, HEU, SNMMI
News | Radiopharmaceuticals and Tracers | October 28, 2016

October 28, 2016 — The National Academies of Sciences, Engineering, and Medicine (NAS) have released a report on the...

Axumin, fluciclovine F-18, PET agent, Phase 3 study, recurrent prostate cancer detection, Blue Earth Diagnostics
News | Prostate Cancer | October 25, 2016

October 25, 2016 — Blue Earth Diagnostics Ltd. announced the peer-reviewed publication of results from a Phase 3...

Lantheus, flurpiridaz F-18, myocardial perfusion imaging, MPI, cardiac stress testing, ASNC 2016
News | Radiopharmaceuticals and Tracers | October 17, 2016

October 17, 2016 — Lantheus Holdings Inc. announced in late September that sub-analysis data from the first Phase 3...

Alzheimer's, ADNI3 study, Alzheimer's Disease Neuroimaging Initiative, NIH grant, MRI, PET, biomarkers
Feature | Neuro Imaging | September 09, 2016

September 9, 2016 — The Alzheimer’s Disease...

Axumin, fluciclovine F-18 injection, first injection, Northside Hospital Atlanta
News | Radiopharmaceuticals and Tracers | September 07, 2016

September 7, 2016 — Blue Earth Diagnostics announced that the first post-U.S. Food and Drug Administration (FDA)...

News | Radiopharmaceuticals and Tracers | September 06, 2016

September 6, 2016 — Navidea Biopharmaceuticals Inc. announced that it has executed a Letter of Intent (LOI) with...

ASNC, SNMMI, position statement, myocardial perfusion PET, coronary artery disease
News | PET Imaging | September 01, 2016

September 1, 2016 — The American Society for Nuclear Cardiology (ASNC) and the Society of...

Lantheus, Xenon 133 gas, radiopharmaceuticals, IRE, Institute for Radioelements Belgium
News | Radiopharmaceuticals and Tracers | July 12, 2016

July 12, 2016 — Lantheus Holdings Inc., the parent company of Lantheus Medical Imaging Inc. (LMI), announced the...

Cell>Point, license agreement, China, United Eastern Pharmaceutical, Oncardia imaging agent
News | Radiopharmaceuticals and Tracers | July 07, 2016

July 7, 2016 — Cell>Point announced in mid-June it has entered into an...

Navidea, Lymphoseek injection, breast cancer detction, scintigraphy, SNMMI 2016
News | Radiopharmaceuticals and Tracers | July 06, 2016

July 6, 2016 — Navidea Biopharmaceuticals Inc. announced results from three investigator-initiated studies of the...